BPC 157 vs TB 500

Written by Johnathon Anderson, Ph.D., a research scientist specializing in regenerative medicine and serving as an Associate Professor at the University of California Davis School of Medicine

What Are BPC-157 And TB-500?

BPC-157 and TB-500 are powerful therapeutic peptides that have been extensively researched. BPC-157 and TB-500 have been shown to promote tissue repair and immune support. Both of these peptides are derived from naturally occurring proteins found in the body but have been slightly modified to enhance their healing capabilities.

BPC-157 vs TB-500: Wound Healing

Both BPC-157 and TB-500 possess strong tissue healing properties and promote tissue regeneration.

• BPC-157 is a peptide that was discovered in gastric juices. BPC-157 stimulates fibroblast proliferation and migration, which are important for wound repair by generating the extracellular matrix. BPC 157 increases collagen deposition in damaged tissue.

• TB-500 is derived from the peptide thymosin beta-4 (Tβ-4). Tβ-4 facilitates wound healing. through its interaction with actin, which facilitates cell migration during the wound-healing process. Tβ-4 regulates the immune system and has been shown to modulate the activity of certain types of white blood cells toward a more anti-inflammatory and tissue healing phenotype.

BPC-157 vs TB-500: Angiogenesis

Though both peptides stimulate blood vessel formation (angiogenesis), they do so differently, impacting their suitability for various healing applications.

• BPC 157 upregulates VEGF receptor gene expression which makes cells more sensitive to the presence of VEGF signaling. This results in increased angiogenesis and blood flow to wounds, as has been demonstrated in a number of preclinical models.

• Tβ4, and therefore potentially TB-500, increases cell viability, angiogenesis and migratory ability of endothelial cells and elevates the gene expression of Ang2, tie2, VEGFA, N1ICD, Notch3, NF-κB. These genes are essential for angiogenesis which increases the blood flow to damaged tissues. This elevates oxygen and nutrient delivery to damaged tissues, which is key for tissue healing and regeneration.

BPC-157 vs TB-500: Cardiovascular Health

• BPC-157 possesses antioxidant properties via its ability to neutralize reactive oxygen species such as malondialdehyde which can damage heart tissue following a cardiac event.

• Tβ4, and therefore potentially TB-500, promotes the growth of collateral blood vessels in cardiac tissue. These blood vessels increase the oxygen supply to heart muscle cells. Tβ4 also has anti-inflammatory properties and helps reduce scar formation, both of which are critical for reducing long-term complications such as heart failure. Published reports indicate that Tβ4-infused gels implanted post-myocardial infarction reduce scarring and increase long-term recovery.

BPC-157 vs TB-500: Gastrointestinal (GI) Healing

• BPC 157 has been shown to facilitate the healing of fistulas, which are related to disorders like Crohn's disease and ulcerative colitis.

• Tβ4, and therefore potentially TB-500, markedly improved disease outcomes for bacterial infection, Pseudomonas aeruginosa-induced keratitis. Tβ4 upregulates antimicrobial peptides, showing an indirect bactericidal role in a synergistic relationship with the antibiotic ciprofloxacin.

BPC-157 vs TB-500: Tendon And Ligament Injuries

• BPC-157 potentiates tendon re-growth following injury by increasing fibroblast cell survival, migration, and growth. Fibroblasts are the cell populations that are most critically responsible for the deposition of the extracellular matrix protein collagen. BPC 157 also elevates gene expression of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) alongside VEGF, all of which support tissue regeneration. Notably, BPC 157 also increases expression of growth hormone receptors, which increase the healing effects from growth hormone signaling factors.

• Tβ4, and therefore potentially TB-500, facilitates musculoskeletal recovery via increases in fibroblast cell migration and actin up-regulation. Fibroblast cells play a crucial role in tissue repair, and Tβ4's ability to enhance their migration to the site of injury enhances tissue healing and ligament and tendon repair. Its angiogenic properties improve blood flow to injured ligaments and tendons, delivering nutrients needed for repair.

BPC-157 vs TB-500: COVID

• BPC-157 may have some anti-coagulant capabilities, which potentially prevent late-stage complications from COVID infection, such as excessive blood clotting. BPC-157 regulates the FAK-Paxillin adhesion system, potentially aiding in clot prevention and blood flow stabilization in infected tissues.

• Tβ4, and therefore potentially TB-500, modulates ACE receptor function, which regulates how the COVID virus gains entry into the cells it infects. The peptide blocks some ACE receptor binding sites, which inhibits the virus from entering some cells.

Combining BPC-157 And TB-500

BPC-157 vs TB-500 both have various tissue healing and regeneration properties, including blood vessel growth and immunoregulation. Therefore, there exists a strong rationale to pursue future research where both BPC-157 and TB-500 are administered together to assess whether they have synergistic healing effects. These peptides cover multiple pathways, potentially enhancing therapeutic outcomes for various injuries and diseases. Both peptides hold unique positions among healing agents, setting a high standard for next-generation therapeutic peptides.

For more info on BPC-157 research.

For more info on TB-500 research.

References

1] T. Huang et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Des. Devel. Ther., vol. 9, pp. 2485–2499, 2015 https://pubmed.ncbi.nlm.nih.gov/25995620/

2] K. N. Dubé and N. Smart, “Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease,” Expert Opin. Biol. Ther., vol. 18, no. sup1, Art. no. sup1, Jul. 2018 https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1459558

3] M.-J. Hsieh et al., “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation,” J. Mol. Med., vol. 95, no. 3, Art. no. 3, Mar. 2017 https://link.springer.com/article/10.1007/s00109-016-1488-y

4] K. M. Kassem, S. Vaid, H. Peng, S. Sarkar, and N.-E. Rhaleb, “Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?,” Can. J. Physiol. Pharmacol., vol. 97, no. 7, pp. 589–599, Jul. 2019 https://cdnsciencepub.com/doi/10.1139/cjpp-2018-0570

5] A. D. Shaghiera, P. Widiyanti, and H. Yusuf, “Synthesis and Characterization of Injectable Hydrogels with Varying Collagen−Chitosan−Thymosin β4 Composition for Myocardial Infarction Therapy,” J. Funct. Biomater., vol. 9, no. 2, p. E33, Apr. 2018 https://www.mdpi.com/2079-4983/9/2/33

6] M. Baric et al., “Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats,” Life Sci., vol. 148, pp. 63–70, Mar. 2016 https://www.sciencedirect.com/science/article/abs/pii/S0024320516300807

7] T. W. Carion et al., “Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis,” Cells, vol. 7, 10, 10, Oct. 2018 https://pmc.ncbi.nlm.nih.gov/articles/PMC6210523/

8] D. Gwyer, N. M. Wragg, and S. L. Wilson, “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing,” Cell Tissue Res., vol. 377, 2, 2, Aug 2019 https://pubmed.ncbi.nlm.nih.gov/30915550/

9] S. Seiwerth et al., “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing,” Curr. Pharm. Des., 24,18, p 1972–1989, 2018 https://www.eurekaselect.com/article/91653

10] C.-H. Chang, W.-C. Tsai, Y.-H. Hsu, and J.-H. S. Pang, “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts,” Mol. Basel Switz., vol 19,11, 11, Nov. 2014 https://www.mdpi.com/1420-3049/19/11/19066

11] J. L. Zhuo et al., “Characterization and localization of Ac-SDKP receptor binding sites using 125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts,” Am. J. Physiol. Heart Circ. Physiol., vol 292, 2, 2, Feb. 2007 https://journals.physiology.org/doi/full/10.1152/ajpheart.00776.2006?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org

12] G. Masuyer, R. G. Douglas, E. D. Sturrock, and K. R. Acharya, “Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme,” Sci. Rep. vol 5, Sep. 2015 https://www.nature.com/articles/srep13742

13] Shumin Lv, Hongwen Cai, Yifei Xu, Jin Dai, Xiqing Rong, Lanzhi Zheng "Thymosin-β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway" Int J Mol Med. 2020 Aug 11;46(4):1347–1358 https://www.spandidos-publications.com/10.3892/ijmm.2020.4701